Taken together, the mutation in RUNX1 in some MDS patients and the RUNX1 epigenetic event shown in in vitro cell culture treated with benzene metabolites may be important if the RUNX1 finding can be reproduced in workers exposed to benzene, especially since this mutation occurs in the target organ of toxicity. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.